1. P174 Effect of continued treatment with pirfenidone following a ≥10% relative decline in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF). (15th November 2016) Authors: Wells, AU; Albera, C; Costabel, U; Glaspole, I; Glassberg, MK; Lancaster, L; Lederer, DJ; Pereira, CA; Swigris, JJ; Day, B-M; Chou, W; Nathan, SD Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S97 Annual rate of fvc decline in various patient sub-groups with idiopathic pulmonary fibrosis treated with pirfenidone: pooled analysis from 3 pivotal studies. (15th November 2016) Authors: Noble, PW; Albera, C; Chou, W; Costabel, U; Day, B; Glaspole, I; Glassberg, MK; Lancaster, L; Lederer, DJ; Nathan, SD; Pereira, CA; Stauffer, J; Swigris, JJ Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P13 Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials. (12th November 2015) Authors: Noble, PW; Albera, C; Bradford, WZ; Costabel, U; Glaspole, I; Glassberg, MK; Lederer, DJ; Lin, Z; Nathan, SD; Pereira, CA; Swigris, JJ; Valeyre, D; Lancaster, L Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S126 Dupilumab efficacy in children with uncontrolled type 2 asthma analyzed by baseline high or medium ICS dose: LIBERTY ASTHMA VOYAGE study. (11th November 2022) Authors: Maspero, JF; Antila, MA; Jean, N; Deschildre, A; Bacharier, LB; Altincatal, A; Rimington, T; Laws, E; Akinlade, B; Radwan, A; Jacob-Nara, JA; Deniz, Y; Rowe, PJ; Lederer, DJ; Hardin, M Journal: Thorax Issue: Volume 77(2022)Supplement 1 Page Start: A77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S109 Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF). (12th November 2015) Authors: Noble, PW; Albera, C; Bradford, WZ; Costabel, U; Glaspole, I; Glassberg, MK; Lancaster, L; Lederer, DJ; Lin, Z; Pereira, CA; Swigris, JJ; Valeyre, D; Nathan, SD Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P14 Pirfenidone is efficacious in patients with idiopathic pulmonary fibrosis (IPF) with more preserved lung function. (12th November 2015) Authors: Noble, PW; Bradford, WZ; Costabel, U; Glaspole, I; Glassberg, MK; Gorina, E; Kardatzke, D; Lancaster, L; Lederer, DJ; Nathan, SD; Pereira, C; Spirig, D; Swigris, JJ; Valeyre, D; Albera, C Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗